- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.
|Summary of Clinical Use
|Eglumegad (LY354740) is a research drug being investigated for efficacy in the treatment of anxiety [3,8] and drug addiction .
|Mechanism Of Action and Pharmacodynamic Effects
|A glutamate derivative, eglumegad is a selective agonist for the group II metabotropic glutamate receptors (mGluR2/3) [1,9]. These receptors reduce the activity of postsynaptic potentials in the cortex by inhibiting the release of glutamate and GABA. This class of drug represents a novel mechanism of action in treating anxiety, as such compounds appear to have no reproducible interaction with dopamine D2 receptors, which are an established drug target in psychosis.